Genoptix Announces Participation At The 2010 UBS Global Life Sciences Conference
CARLSBAD, Calif., Sept. 13 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today announced the Company's participation at the 2010 UBS Global Life Sciences Conference at the Grand Hyatt Hotel in New York City, to be held September 20-22, 2010.
President and CEO Tina S. Nova, Ph.D., and Sam Riccitelli, EVP and COO of Genoptix, will present at the conference on Tuesday, September 21, 2010 beginning at noon EDT, when they will provide an overview of the Company's specialized diagnostic laboratory services business, growth strategies and financial performance.
The presentation is expected to last approximately 30 minutes and will be webcast live through the "Investors" section of the Genoptix website at www.genoptix.com. Those who would like to listen to the presentation should go to this site at least 15 minutes prior to the event to register, download and install any necessary software. An audio replay will be available for 30 days following the initial presentation webcast.
About Genoptix, Inc.Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix's highly trained group of hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports. Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma, and other forms of cancer. Founded in 1999, Genoptix is a member of the Nasdaq Global Select Market, the S&P SmallCap 600 Index and the Russell 2000 Index and is headquartered in Carlsbad, California. For more information, please visit www.genoptix.com. Forward-Looking Statements This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Genoptix disclaims, however, any intent or obligation to update these forward-looking statements. SOURCE Genoptix, Inc.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts